Skip to Main Content

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Remember, a prescription is not required. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. …

Pfizer (PFE) and BioNTech (BNTX) submitted data to the Food and Drug Administration needed to clear a Covid-19 booster shot for the general public, The Wall Street Journal notes. The companies sent results from a small, early-stage study showing a third dose of their vaccine generated higher levels of neutralizing antibodies against the original virus and against the Beta and Delta variants than the standard two-dose regimen. The addition of the third dose also appeared safe in the trial, the drug makers added.


Less than two months after the FDA authorized emergency use of Actemra for critically ill Covid-19 patients, Roche (RHHBY) disclosed that global shortages will exist over the coming weeks and months. The drug maker cited an “unprecedented surge in worldwide demand,” with U.S. demand spiking well beyond 400% of what was seen prior to the pandemic. Much of the clamor in the U.S. occurred in the past two weeks alone.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.